Published on

Medicine - Mast Cells and Basophils

Mast cells and basophils are granule-containing immune cells involved in Type I (immediate) hypersensitivity, allergic inflammation and immune responses against parasitic infections, particularly helminths.

Both express high-affinity receptors for immunoglobulin E (IgE), known as FcεRI receptors.

When an allergen cross-links IgE molecules bound to these receptors, the cells become activated and release inflammatory mediators, including histamine, leukotrienes, prostaglandins and proteases.

Key Examination Associations
  • Basophils circulate predominantly in blood.
  • Mast cells are predominantly tissue-resident.
  • Both express high-affinity IgE receptors (FcεRI).
  • Histamine and proteases are stored in cytoplasmic granules.
  • Prostaglandins and leukotrienes are synthesised following activation.
  • Participate in immune responses against helminths.
  • Important in Type I immediate hypersensitivity.
  • Allergen-induced IgE cross-linking triggers cellular activation.

1. Distribution and Characteristics

A. Basophils

Basophils are circulating granulocytes derived from haematopoietic stem cells in the bone marrow.

Characteristics:
  • Found predominantly in peripheral blood.
  • Constitute approximately 0-1% of circulating white blood cells.
  • Contain large, dark blue-purple cytoplasmic granules.
  • Have a lobed nucleus that may be obscured by granules.
  • Express high-affinity FcεRI receptors.
  • Participate in allergic inflammation and type 2 immune responses.

Basophils can migrate into inflamed tissues but are primarily circulating cells.

B. Mast Cells

Mast cells are tissue-resident immune cells that develop from bone marrow-derived precursors.

Unlike basophils, mast-cell precursors generally complete maturation after entering tissues.

Common locations:
  • Skin.
  • Respiratory mucosa.
  • Gastrointestinal mucosa.
  • Connective tissue.
  • Around blood vessels.
  • Near peripheral nerves.

Mast cells are particularly abundant at interfaces between the body and the external environment.

C. Mast Cells Versus Basophils

Feature Mast Cells Basophils
Main locationTissuesBlood
MaturationPredominantly in tissuesBone marrow
Cell typeTissue-resident immune cellCirculating granulocyte
NucleusUsually round or ovalOften lobed
GranulesHistamine, proteases, heparinHistamine and other mediators
IgE receptorFcεRIFcεRI
Major functionsAllergy, tissue inflammation, parasite defenceAllergy, cytokine production, parasite-associated responses
High-Yield Distinction: Basophils = Blood.
Mast cells = Tissues.

2. Origin and Development

Mast cells and basophils originate from haematopoietic stem cells but follow distinct differentiation pathways.

Visual Flowchart: Mast-Cell and Basophil Development

Haematopoietic Stem Cell Bone marrow Myeloid Progenitor Basophil Lineage Bone marrow maturation Mast-Cell Lineage Precursor migration to tissues Basophils Circulate in blood Mast Cells Mature in tissues

Mast-cell development and survival are strongly influenced by stem cell factor (SCF) acting through the KIT receptor (CD117).

3. Inflammatory Mediators

Mast cells and basophils release inflammatory mediators after activation.

These can be divided into preformed mediators, newly synthesised lipid mediators and cytokines.

A. Preformed Mediators

Preformed mediators are stored in cytoplasmic granules and can be released rapidly.

1. Histamine

  • Vasodilation.
  • Increased vascular permeability.
  • Oedema.
  • Bronchoconstriction.
  • Itching (pruritus).
  • Increased mucus secretion.

2. Proteases

  • Tryptase.
  • Chymase.

Mast-cell proteases contribute to tissue remodelling, inflammation and local immune responses.

Clinical association: Serum tryptase may rise after systemic mast-cell activation, including anaphylaxis.

3. Heparin

Mast-cell granules contain heparin and related proteoglycans that help organise and store granule mediators.

B. Newly Synthesised Lipid Mediators

1. Prostaglandins

Prostaglandin D2 (PGD2) is an important mast-cell-derived prostaglandin.

  • Bronchoconstriction.
  • Vasodilation.
  • Recruitment of inflammatory cells.

2. Leukotrienes

Important cysteinyl leukotrienes include:

  • LTC4.
  • LTD4.
  • LTE4.
Effects:
  • Potent bronchoconstriction.
  • Increased vascular permeability.
  • Increased mucus secretion.
  • Prolonged allergic inflammation.

C. Cytokines

Cytokine Function
IL-4Th2 differentiation and IgE-associated responses
IL-13Mucus production and type 2 inflammation
TNFInflammation and leukocyte recruitment
IL-5Eosinophil-associated responses in appropriate settings

Summary of Inflammatory Mediators

Mediator Main Effect
HistamineVasodilation, permeability, itching, bronchoconstriction
PGD2Bronchoconstriction and inflammation
LTC4, LTD4, LTE4Bronchoconstriction, oedema, mucus secretion
TryptaseProteolysis and tissue inflammation
IL-4Type 2 immunity and IgE responses
IL-13Mucus production and airway inflammation
Important Distinction: Histamine and proteases are stored in granules. Prostaglandins and leukotrienes are predominantly synthesised following activation.

4. Type I (Immediate) Hypersensitivity

Type I hypersensitivity is an IgE-mediated immune reaction that typically occurs rapidly after allergen exposure in a previously sensitised individual.

Examples:
  • Anaphylaxis.
  • Allergic rhinitis.
  • Allergic asthma.
  • Acute urticaria.
  • Some food allergies.

A. Sensitisation Phase

During the first relevant exposure to an allergen:

  1. The allergen is captured and processed by antigen-presenting cells.
  2. CD4+ T cells may differentiate into Th2 cells.
  3. IL-4 and IL-13 support IgE class switching in B cells.
  4. Plasma cells produce allergen-specific IgE.
  5. IgE binds to FcεRI receptors on mast cells and basophils.

The individual is now sensitised to the allergen.

B. Effector Phase

During subsequent allergen exposure:

  1. The allergen binds to IgE attached to FcεRI.
  2. Adjacent receptor-bound IgE molecules are cross-linked.
  3. Intracellular signalling activates the cell.
  4. Rapid degranulation releases preformed mediators.
  5. New lipid mediators and cytokines are produced.
  6. Clinical allergic symptoms develop.

Visual Flowchart: IgE-Mediated Hypersensitivity

First Allergen Exposure Sensitisation phase Th2-Associated Response IL-4 and IL-13 Support IgE class switching IgE Production Plasma cells secrete IgE IgE Binds FcεRI Mast cells and basophils Subsequent Allergen Exposure Effector phase IgE Cross-Linking Cell activation Mediator Release Histamine, leukotrienes, prostaglandins and cytokines
Exam Point: Type I hypersensitivity occurs when an allergen cross-links IgE already bound to FcεRI receptors, triggering mast-cell or basophil activation.

5. Early and Late Phases of Type I Hypersensitivity

A. Immediate (Early) Phase

The early phase usually begins within minutes of allergen exposure.

Important mediators:
  • Histamine.
  • Prostaglandin D2.
  • Cysteinyl leukotrienes.
Effects:
  • Vasodilation.
  • Increased vascular permeability.
  • Bronchoconstriction.
  • Mucus secretion.
  • Itching.

B. Late-Phase Reaction

The late-phase reaction develops over subsequent hours and involves recruitment and activation of inflammatory cells.

Important cells:
  • Eosinophils.
  • Th2 cells.
  • Basophils.
  • Other leukocytes.
Consequences:
  • Persistent inflammation.
  • Tissue oedema.
  • Sustained airway hyperreactivity.
  • Mucosal injury.

The late-phase reaction is particularly important in allergic asthma and chronic allergic inflammation.

6. Role in Parasitic Infections

Mast cells and basophils contribute to type 2 immune responses against parasites, especially helminths.

Mechanisms:
  • Release inflammatory mediators.
  • Support recruitment of immune cells.
  • Promote mucus secretion.
  • Increase intestinal smooth-muscle activity.
  • Contribute to parasite expulsion.
  • Produce cytokines supporting type 2 immunity.

Important Th2 Cytokines

  • IL-4: Promotes IgE class switching.
  • IL-5: Supports eosinophil development and activation.
  • IL-13: Promotes mucus secretion and epithelial responses.

Visual Flowchart: Anti-Helminth Immunity

Helminth Infection Type 2 Immune Response IL-4, IL-5 and IL-13 IgE and Mast Cells Mediator release Barrier responses Eosinophils Granule-mediated parasite injury Parasite Defence and Expulsion

7. Clinical Associations

A. Anaphylaxis

Anaphylaxis is a severe, potentially life-threatening systemic hypersensitivity reaction involving rapid mediator release from mast cells and, in some cases, basophils.

Possible features:
  • Generalised urticaria.
  • Angioedema.
  • Bronchospasm.
  • Hypotension.
  • Gastrointestinal symptoms.
  • Circulatory collapse.
Important Clinical Point: Intramuscular adrenaline (epinephrine) is the first-line treatment for anaphylaxis. Antihistamines are not substitutes for adrenaline.

B. Allergic Asthma

  • Bronchoconstriction.
  • Airway oedema.
  • Mucus hypersecretion.
  • Airway inflammation.

Leukotrienes are particularly important mediators of bronchoconstriction.

C. Allergic Rhinitis

  • Sneezing.
  • Rhinorrhoea.
  • Nasal itching.
  • Nasal congestion.

D. Urticaria

Mast-cell mediator release in the skin causes transient, itchy wheals.

Some forms are IgE-mediated, while others involve different mast-cell activation mechanisms.

E. Mastocytosis

Mastocytosis involves abnormal accumulation of mast cells in tissues.

Possible manifestations:
  • Flushing.
  • Pruritus.
  • Urticaria-like skin lesions.
  • Gastrointestinal symptoms.
  • Anaphylaxis.

Systemic mastocytosis is frequently associated with activating mutations in the KIT gene, particularly KIT D816V.

F. Mast Cell Activation Syndrome (MCAS)

MCAS refers to episodes of systemic symptoms attributable to mast-cell mediator release, supported by appropriate clinical and laboratory criteria.

Mast-cell activation may occur through IgE-dependent or IgE-independent mechanisms.

8. Pharmacological Associations

Drug Class Mechanism Examples
H1 antihistaminesBlock H1 receptor effectsCetirizine, loratadine
Leukotriene receptor antagonistsBlock cysteinyl leukotriene receptorsMontelukast
Mast-cell stabilisersReduce mast-cell activation and mediator releaseCromolyn sodium
Anti-IgE therapyReduces free IgE and downstream FcεRI signallingOmalizumab
AdrenalineTreats systemic effects of anaphylaxisEpinephrine

9. Important Corrections

  1. Basophils circulate predominantly in blood but can enter inflamed tissues.
  2. Mast cells are predominantly tissue-resident and complete much of their maturation in tissues.
  3. Both cells contain preformed mediators and can synthesise additional mediators after activation.
  4. Histamine and proteases are stored in granules, whereas prostaglandins and leukotrienes are predominantly synthesised after activation.
  5. Mast cells and basophils participate in anti-parasitic responses, particularly against helminths.
  6. Type I hypersensitivity commonly involves allergen-induced cross-linking of IgE bound to FcεRI.
  7. Mast cells can also be activated through IgE-independent pathways.
  8. Eosinophils are additional important effector cells in helminth immunity and allergic inflammation.

10. High-Yield Examination Summary

Distribution
  • Basophils: Blood.
  • Mast cells: Tissues.
Major Mediators
  • Histamine.
  • Prostaglandins.
  • Leukotrienes.
  • Proteases.
  • Cytokines.
Main Functions
  • Type I immediate hypersensitivity.
  • Allergic inflammation.
  • Helminth defence.
Important Mechanism
  • Allergen cross-links IgE bound to FcεRI.
  • Mast-cell or basophil activation.
  • Degranulation and mediator synthesis.
  • Allergic symptoms.
Clinical Associations
  • Anaphylaxis.
  • Allergic asthma.
  • Allergic rhinitis.
  • Urticaria.
  • Mastocytosis.
Most Important Examination Point:

Basophils circulate in blood, while mast cells are predominantly tissue-resident.

Both participate in Type I hypersensitivity through allergen-induced cross-linking of receptor-bound IgE, leading to mediator release and immediate allergic inflammation.

Medicine - Immunology Revision Notes

Image description
0 Comments